The U.S. government is stepping up efforts to find a successful treatment for Ebola with more funding going to a Triangle company.

The National Institute of Allergy and Infectious Diseases has provided another $4.1 million in funding to Triangle-based BioCryst Pharmaceuticals for further development of a potential vaccine.

No current treatment exists. Drug giant GlaxoSmithKline (NYSE: GSK) is attempting to develop one as well.

BioCryst (Nasdaq: BCRX) announced the funding Wednesday.

The NIAID has worked with BioCryst since September of last year, pledging support of $22 million. The latest deal pushes the total committed thus far to $13.5 million.

“The ongoing Ebola epidemic in West Africa emphasizes the urgent need for safe and effective antiviral agents for hemorrhagic fever virus diseases. With these additional funds, BioCryst can move forward with important non-human primate efficacy studies, an IND filing, and Phase 1 human trials of intramuscular BCX4430,” said Dr. William P. Sheridan, Chief Medical Officer at BioCryst, in a statement.

“We look forward to the body of evidence supporting BCX4430 evolving into a highly compelling package, enabling us to attract U.S. Government advanced development funding,” he added. “This is critical so that a new drug application can be filed as quickly as feasible for this unique, broad spectrum antiviral.”

NIAID is part of the National Institutes of Health.